• Explore /
  • Poster
  • / Phase I/II study of R-ICE (rituximab-ifosfamide-carboplatin-etoposide) with lenalidomide (R2-ICE) in patients with first-relapse/primary refractory diffuse large B-cell lymphoma (DLBCL) in academic and community cancer research united (ACCRU) network.

Phase I/II study of R-ICE (rituximab-ifosfamide-carboplatin-etoposide) with lenalidomide (R2-ICE) in patients with first-relapse/primary refractory diffuse large B-cell lymphoma (DLBCL) in academic and community cancer research united (ACCRU) network.

Abstract Video & Slides Poster

Authors

null

Francis Guerra-Bauman

Mayo Clinic, Rochester, MN

Francis Guerra-Bauman , Betsy LaPlant , William R. Macon , Thomas E. Witzig , Umar Farooq , Grzegorz S. Nowakowski , Tatyana Feldman

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies

Sub Track

Non-Hodgkin Lymphoma

Clinical Trial Registration Number

NCT02628405

Citation

J Clin Oncol 38: 2020 (suppl; abstr TPS8073)

DOI

10.1200/JCO.2020.38.15_suppl.TPS8073

Abstract #

TPS8073

Poster Bd #

406

Abstract Disclosures

Similar Posters

First Author: Yucai Wang

First Author: G. S. Nowakowski

First Author: Joanna S. Yi

First Author: Cyrille Touzeau